Physician profile
Nancy Chodash
NPI 1346371051
$4,680.20
in general payments reported to CMS, 2019-2025
33 companies · $1,467 in 2025
The $1,467 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $584 · 2022: $712 · 2023: $961 · 2024: $956 · 2025: $1,467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,383.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $653.60 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $639.16 | 2022-2025 | |
| Lilly USA, LLC | $452.99 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.46 | 2021-2025 | Jardiance, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $351.63 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Axsome Therapeutics, INC. | $336.89 | 2023-2025 | Auvelity |
| Pfizer INC. | $285.81 | 2023-2025 | |
| Amgen INC. | $219.31 | 2021-2025 | Evenity |
| Currax Pharmaceuticals LLC | $218.47 | 2021-2025 | Contrave |
| Takeda Pharmaceuticals U.S.A., INC. | $169.07 | 2021-2024 | Trintellix |
| Boston Scientific Corporation | $147.36 | 2025 | Overstitch Endoscopic Suturing System, General - Pain Management |
| Corcept Therapeutics | $124.61 | 2025 | Korlym |
| Biohaven Pharmaceutical Holding Company LTD. | $112.32 | 2022 | |
| Glaxosmithkline, LLC. | $70.65 | 2022-2023 | Shingrix, Trelegy Ellipta |
| Exact Sciences Corporation | $54.44 | 2023-2024 | Cologuard Collection Kit |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $51.72 | 2022-2023 | Rexulti |
| Abbott Laboratories | $40.23 | 2025 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $38.45 | 2022-2023 | Linzess |
| Vanda Pharmaceuticals INC. | $35.14 | 2021 | |
| Ibsa Pharma INC. | $33.82 | 2021-2022 | |
| Eisai INC. | $30.35 | 2021 | |
| Merck Sharp & Dohme LLC | $28.13 | 2021 | |
| Astellas Pharma US INC | $25.04 | 2023 | |
| Idorsia Pharmaceuticals US INC | $24.97 | 2023 | Quviviq |
| Edwards Lifesciences Corporation | $24.35 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Agile Therapeutics, INC. | $21.84 | 2021 | |
| Hologic Sales and Service, LLC | $20.71 | 2025 | Aptima |
| Amarin Pharma, INC. | $20.05 | 2021 | |
| Supernus Pharmaceuticals, INC. | $19.22 | 2024 | Qelbree |
| Novartis Pharmaceuticals Corporation | $17.01 | 2023 | |
| Amneal Pharmaceuticals LLC | $14.64 | 2021 | |
| Esperion Therapeutics, INC. | $13.44 | 2021 | |
| Genentech USA, INC. | $4.32 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Chodash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.